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E-mail address: andreas.junker@med.uni-goettingeMicroRNAs (miRNAs) comprise a group of several hundred, small non-coding RNA molecules with a
fundamental inﬂuence on the regulation of gene expression. Certain miRNAs are altered in blood
cells of multiple sclerosis (MS), and active and inactive MS brain lesions have distinct miRNA expres-
sion proﬁles.
Several miRNAs such as miR-155 or miR-326 are considerably overexpressed in active MS lesions
versus controls, and mice lacking these miRNAs either through knock-out (miR-155) or by in vivo
silencing (miR-326) show a reduction of symptoms in experimental autoimmune encephalomyelitis
(EAE), a model system for multiple sclerosis.
This review describes miRNAs regulated in the blood or in brain lesions of MS patients in the con-
text of their previously described functions in physiology and pathophysiology.
 2011 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Recent work on microRNAs (miRNAs) has added a new level of
complexity to our understanding of gene expression and new in-
sights into their contribution to many diseases associated with
the immune system and inﬂammation.
Mature miRNAs are single-stranded RNA molecules approxi-
mately 22 nucleotides in length, which derive from larger hair-
pin-folded RNA precursors called premiRNA. (For review see [1].)
The function of mature miRNAs is translational inhibition or degra-
dation of a target messenger RNA (mRNA), which is achieved by
binding miRNAs to speciﬁc target sequences in the 30UTR of their
target mRNA [2,3]. Notably, one miRNA may have several hundred
mRNA target genes [4,5] and the expression of more than one-third
of all mammalian genes might be regulated by miRNAs [6].
Several hundred miRNAs have so far been identiﬁed in humans
[7], although the number of predicted small non-coding RNAs is
more than one thousand. Two important nucleases involved in
the processing of miRNAs are Dicer and Drosha. The removal of
the Dicer gene is frequently used in in vivo models to deﬁne the
involvement of miRNAs in a particular regulatory process. It has
become clear in recent years that human miRNAs are for the mostlf of the Federation of European B
erosis;Treg cells, regulatory T
n.depart highly conserved in other species, especially other mammals
[8–10].
Posttranscriptional regulation by miRNAs plays an important
role in development but also many biological processes in adult-
hood can be inﬂuenced. Several miRNAs are highly expressed in
speciﬁc cell types and during particular stages of development
[11,12].
It is increasingly recognized that miRNAs play essential roles in
the immune system [13–15] anfor correct function in the mature
CNS [16,17]. It was found that miRNAs are critical for the mainte-
nance of immune tolerance, as can be seen in mice with a deletion
of Dicer-mediated miRNA processing in regulatory T cells (Treg
cells). These mice develop a fatal autoimmune disease which is
very similar to the autoimmune syndrome of animals with a com-
plete deﬁciency of Treg cells [18,19]. Moreover, inﬂammatory cyto-
kines can regulate the expression levels of miRNAs in a distinct cell
type as shown, for example, in astrocytes [20].
The involvement of miRNAs in the pathogenesis of diverse dis-
eases such as cancer, cardiac failure, and neurodegenerative dis-
eases such as Alzheimer’s and Parkinson’s disease, has been
demonstrated [17,21–25].
MiRNAs are suited for therapeutic targets, as could be demon-
strated with animal models of diverse diseases [26–28] and might
presumably lead to new therapeutic strategies for autoimmune
diseases such as multiple sclerosis (MS).
Only recently miRNA expression was detected in the context of
MS. Six papers have been published in which proﬁles of miRNAs
were found in the peripheral blood of MS patients [29–34] andiochemical Societies. Open access under CC BY-NC-ND license.
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of different activity in MS patients [20].
Dysregulation of inﬂammation, demyelination and axonal dam-
age constitute the basis of pathology in multiple sclerosis, but it is
still unclear how the disease is initiated and becomes chronic. A
complex interaction between inﬁltrating immune cells and brain-
resident cells leads to the development of lesions [35–37]. Activa-
tion of macrophages and microglia plays a crucial role in the active
phase of the inﬂammation in the lesions during the breakdown of
the myelin sheath [37–39]. So far, approaches searching for new
insights into the pathogenesis of multiple sclerosis have been
based on the examination of transcripts or the analysis of proteins
either in vitro or in situ, ranging from the examination of the tran-
scriptome of MS lesions [40] to the scrutiny of proteome of MS le-
sions [41]. Posttranscriptional regulation and modiﬁcation of the
translational level is increasingly recognized.
This review will discuss the potential involvement of miRNAs,
with their prospective regulatory function in the pathogenesis of
MS. The main focus will be on the characterization of miRNAs that
has so far emerged from investigations into miRNA alterations in
MS.2. MiRNA proﬁling of blood and brain lesions from MS patients
In the past few years it has been shown that different patterns
of early active inﬂammatory lesions exist in the brain of MS pa-
tients [42]. With the profound heterogeneity in clinical course,
neuroradiological appearance of the lesions, involvement of sus-
ceptibility gene loci, and response to therapy, it would seem that
multiple sclerosis comprises a large number of heterogeneous dis-
eases. Apart from this, Neuromyelitis optica is deﬁned as a separate
inﬂammatory demyelinating disorder [43].
2.1. Will it be possible to deﬁne different disease entities with speciﬁc
miRNA proﬁles?
Recently, speciﬁc lesion proﬁles of active and inactive lesions
were described in the brains of MS patients [20]. Different miRNA
proﬁles were found, depending on the activity of the lesions. Apart
from this miRNA proﬁles were quantiﬁed in the blood of MS pa-
tients and showed differentially expressed miRNAs in MS patients
versus healthy subjects [29–34].
The abundance of miRNAs in the peripheral blood might be
inﬂuenced by the starting material (i.e. whole blood or puriﬁed
blood leukocytes), the method of normalization, the method of
quantiﬁcation (array technology or quantitative PCR) or different
therapies of the patients. All of these factors might inﬂuence differ-
ences between the studies of miRNA expression in the blood of MS
patients. Brain lesion proﬁles might be inﬂuenced by the cellular
composition and the regulation of miRNAs in the invading inﬂam-
matory cells as well as their regulation in brain-resident cells.
Despite these difﬁculties in miRNA proﬁling, there is some over-
lap between the studies. Interestingly, some of the miRNAs which
were found to be regulated in active or inactive brain lesions also
occurred in the blood of MS patients. Table 1 provides an overview
of miRNAs, which were found to be regulated in MS in more than
one expression study up till now.
The miR-326 upregulated in relapsed patients [31] was one of
the most upregulated miRNAs in active MS lesions, especially in
a very active form of the disease called the Marburg variant of
MS [20]. The Marburg variant of MS describes a very fulminant dis-
ease course which often leads to the death of the patient and which
displays all the histopathological features of active MS lesions,
including the inﬁltration of immune cells, the phagocytosis of mye-
lin and the degeneration of axons.Lindberg and colleagues showed miRNA alterations in CD4+ T
cells, CD8+ T cells and B cells from 23 untreated MS patients as
compared to healthy controls [33]. Ten miRNAs were identiﬁed
as being regulated in CD4+ T cells from patients, in comparison
to analogously prepared cells from healthy subjects. In CD8+ T cells,
four miRNAs were conspicuous and six miRNAs were differentially
expressed in B cells in MS subjects. In subjects with MS, miR-497
was upregulated in CD4+ T cells and B cells, whereas it was down-
regulated in CD8+ T cells. Moreover, miR-193a was upregulated in
CD4+ T cells and miR-34a was downregulated in these cells. Finally
miR-629 was upregulated in CD8+ T cells, but miR-30a-3p ap-
peared to be downregulated. Some of the miRNAs found to be reg-
ulated in blood cell subsets in MS patients in comparison to
controls also appeared in active or inactive MS brain lesions.
MiR-497, miR-629 and miR-30a-3p were upregulated in inactive
lesions and miR-193a and miR-34a were upregulated in active le-
sions as compared to controls [20].
A recent study by Keller and colleagues described diverse miR-
NA expression proﬁles in whole blood cells of MS patients com-
pared with healthy controls, and identiﬁed a number of miRNAs
that were up- or downregulated [32]. Of the ten most signiﬁcantly
regulated miRNAs in this study, miR-142-3p and miR-223 were
upregulated in active MS lesions [20].
De Santis and colleagues isolated CD4+CD25high Treg cells from
12MS patients and 14 healthy donors and examined the expression
of 723 miRNAs by microarray analysis [30]. The expression of 23
miRNAs was altered more than 1.5 fold in MS versus healthy Treg
cells. Most of these miRNAs were upregulated in MS versus healthy
controls and only a few of them appeared to be downregulated.
MiR-223 was also reported in this study as being upregulated in
Treg cells fromMS subjects. Among the other upregulated miRNAs,
miR-15a and miR-22 were overexpressed in active lesions in the
brains of MS patients [20] and miR-148a was upregulated in inac-
tive lesions in comparison to normal brains [20].
Cox and colleagues measured miRNAs using microarray analy-
sis in the peripheral blood of 59 untreated MS patients and 37 con-
trols [29]. Of these 59, 18 had a primary progressive, 17 a
secondary progressive and 24 a relapsing-remitting disease course.
They found that miR-17 and miR-20a were signiﬁcantly underex-
pressed in all MS subtypes.
It is reasonable that in MS, activity of the disease and the occur-
rence of relapses or phases of remission might alter the miRNA
proﬁle in the peripheral blood of MS patients. Evidence for this de-
rives from two different recent reports which demonstrated miR-
NA alterations in the blood of MS patients during relapses in
comparison to healthy controls [31,34]. Otaegui and colleagues
showed an upregulation of three miRNAs (miR-18b, miR-493 and
miR-599) during relapses [34]. However their results did not reach
clearly signiﬁcant levels, which might be due to the small number
of patient samples examined. The expression of miR-326 was re-
ported to be elevated in the peripheral blood leukocytes of patients
with MS, especially during relapses [31]. This miRNA participates
in the differentiation of Th-17 cells in a mouse model, which could
also be demonstrated in this study [31]. Th-17 cells might play an
important role in the pathophysiology of MS [44,45].
Cox and colleagues showed in their study that miR-17 and miR-
20a modulate T cell activation genes in a knock-in and knock-down
T cell model [29]. They also described these miRNAs as signiﬁ-
cantly downregulated in MS whole blood cells. These two miRNAs
belong to a cluster of 7 different miRNAs, the so-called miR-17-92
cluster. Interestingly, miRNAs of this cluster were upregulated in
the study by Lindberg and colleagues [33]. The described regula-
tion was contrary in these two studies, which could be due to
differences in the studied material (one of the studies used whole
blood, in comparison to B cells and CD4+ and CD8+ T cells puriﬁed
from peripheral blood mononuclear cells), the method of quantiﬁ-
Table 1
miRNAs regulated in multiple sclerosis.
miRNAa Regulated in tissue Detection method Ref.
miR-629 Upregulated in inactive MS brain white matter lesions versus normal brain white matter qPCR [20]e
Upregulated in CD8+ T cells from blood samples from MS patients versus healthy controls qPCR [33]g
miR-497 Upregulated in inactive MS brain white matter lesions versus normal brain white matter qPCR [20]e
Upregulated in CD4+ T cells and B cells from blood samples from MS patients versus healthy controls,
downregulated in CD8+ T cells from blood samples from MS patients versus healthy controls
qPCR [33]g
miR-422a Upregulated in whole blood samples from MS patients in comparison to healthy donors Microarray analysis [32]f
Downregulated in B cells from blood samples from MS patients versus healthy controls qPCR [33]g
miR-326 Upregulated in active MS brain white matter lesions versus normal brain white matter qPCR [20]e
Upregulated in peripheral blood leukocytes of MS Patients with relapses versus comparable cells from normal
controls
qPCR [31]c
miR-223 Upregulated in whole blood samples from MS patients in comparison to healthy donors Microarray analysis [32]f
Upregulated in active MS brain white matter lesions versus normal brain white matter qPCR [20]e
Upregulated in CD4+CD25high bona ﬁde Treg cells from MS Patients versus comparable cells from healthy donors Microarray analysis [30]b
miR-193a Upregulated in active MS brain white matter lesions versus normal brain white matter qPCR [20]e
Upregulated in CD4+ T cells from blood samples from MS patients versus healthy controls qPCR [33]g
miR-155 Upregulated in active MS brain white matter lesions versus normal brain white matter qPCR [20]e
miR-155-/- mice were highly resistant to experimental autoimmune encephalomyelitis (EAE) [48]
miR-148a Upregulated in inactive MS brain white matter lesions versus normal brain white matter qPCR [20]e
Upregulated in CD4+CD25high bona ﬁde Treg cells from MS Patients versus comparable cells from healthy donors Microarray analysis [30]b
miR-142-3p Upregulated in whole blood samples from MS patients in comparison to healthy donors Microarray analysis [32]f
Upregulated in active MS brain white matter lesions versus normal brain white matter qPCR [20]e
miR-126 Upregulated in CD4+ T cells from blood samples from MS patients versus healthy controls qPCR [33]g
Downregulated in whole blood samples from MS patients versus healthy controls Microarray analysis [29]d
Upregulated in inactive MS brain white matter lesions versus normal brain white matter qPCR [20]e
miR-93 Upregulated in CD4+CD25high bona ﬁde Treg cells from MS Patients versus comparable cells from healthy donors Microarray analysis [30]b
Downregulated in whole blood samples from MS patients versus healthy controls Microarray analysis [29]d
miR-34a Upregulated in active MS brain white matter lesions versus normal brain white matter qPCR [20]e
Downregulated in CD4+ T cells from blood samples from MS patients versus healthy controls qPCR [33]g
miR-30a-3p Upregulated in inactive MS brain white matter lesions versus normal brain white matter qPCR [20]e
Downregulated in CD8+ T cells from blood samples from MS patients versus healthy controls qPCR [33]g
miR-27a Upregulated in active MS brain white matter lesions versus normal brain white matter qPCR [20]e
Downregulated in whole blood samples from MS patients versus healthy controls Microarray analysis [29]d
miR-22 Upregulated in active MS brain white matter lesions versus normal brain white matter qPCR [20]d
Upregulated in CD4+CD25high bona ﬁde Treg cells from MS Patients versus comparable cells from healthy donors Microarray analysis [30]b
miR-20b Downregulated in whole blood samples from MS patients in comparison to healthy donors Microarray analysis [32]f
Downregulated in whole blood samples from MS patients versus healthy controls Microarray analysis [29]d
Upregulated in inactive MS brain white matter lesions versus normal brain white matter qPCR [20]e
miR-15a Upregulated in CD4+CD25high bona ﬁde Treg cells from MS Patients versus comparable cells from healthy donors Microarray analysis [30]b
Upregulated in active MS brain white matter lesions versus normal brain white matter qPCR [20]e
Downregulated in whole blood samples from MS patients versus healthy controls Microarray analysis [29]d
let-7i Downregulated in whole blood samples from MS patients versus healthy controls Microarray analysis [29]d
Upregulated in CD4+CD25high bona ﬁde Treg cells from MS Patients versus comparable cells from healthy donors Microarray analysis [30]b
a Only those miRNAs were included which appeared to be regulated in more than one MS miRNA expression study or which were relevant in an EAE model.
b Subjects: 12 patients with relapsing-remitting MS with a stable disease course; 14 healthy controls (for validation 10 MS patients and 10 controls); treatment: no
immunomodulatory treatment.
c Subjects: 43 patients with relapsing-remitting MS (25 in relapse, 18 in remission); 11 patients with NMO (5 in relapse, 6 in remission); 42 controls; treatment: no drug
treatment.
d Subjects: 59 patients with different disease course (18 primary progressive MS, 17 secondary progressive MS, 24 relapsing-remitting MS); 37 healthy controls; treatment:
no immunomodulatory therapy within the previous 3 months.
e Brain specimens: 16 active lesions and 5 chronic inactive lesions from 20 autopsy cases with MS, 9 control white matter specimens from 9 control cases without any
known neurological disease; treatment: not determined.
f Subjects: 20 patients with relapsing-remitting MS; 19 healthy controls; treatment: 9 patients with glatiramer acetate, 10 patients with interferon-b, 1 patient without
any disease-modifying therapy.
g Subjects: 23 patients with relapsing-remitting MS; treatment: no immunomodulatory or MS-speciﬁc treatment within the previous 6 months.
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els. Despite the contrary results, the abnormality in the expression
of this miRNA cluster shows its signiﬁcance in the pathogenesis of
MS. It has already been demonstrated that the miR-17-92 cluster
contributes to the development of autoimmunity in the presence
of serum auto-antibodies and a lymphoproliferative disease in
mice [49]. In this mouse model, the number of mature CD4+ T cells
was markedly increased and they had a highly activated proﬁle,
indicating a failure of peripheral tolerance.
3. Contribution of miRNAs to myelination
Destruction and insufﬁcient regeneration of the myelin sheath
are characteristic hallmarks of MS. While in the early phase of
MS, remyelination can be observed relatively frequently, in later
stages of the disease this process is less effective. Up to now it isnot clear whether all the mechanisms which regulate developmen-
tal myelination have the same effects during remyelination. For
example, in contrast to developmental myelination, Notch signal-
ing seems not to be a rate-determining factor in experimental
remyelination [50]. Despite this some of themechanisms which ex-
ert inﬂuence on developmental myelination have conserved roles
in remyelination. For instance the regulation of Lingo-1 has inﬂu-
ence on developmental myelination [51]. Lingo-1 is expressed in
oligodendrocytes and it is a strong negative regulator of the differ-
entiation of oligodendrocytes as well as axonal myelination. Loss of
Lingo-1 led to a considerably enhanced myelination in a mouse
model, whereas overexpression of Lingo-1 caused an inhibition of
oligodendrocyte differentiation andmyelination [51]. It also modu-
lates the remyelination in animal models of demyelination [52].
It has recently been reported that miRNAs play a relevant role in
the process of developmental myelination. Whether this can be
Fig. 1. Involvement of miRNAs in myelination: miRNAs modulate oligodendrocyte
proliferation and differentiation. High miRNA levels of, eg. miR-219 or miR-338 and
others, lead to the differentiation of oligodendrocyte precursor cells (OPC) by
targeting factors like PDGFRa, Sox6, FoxJ3, and ZFP238. None of these proteins are
affected by miRNA inhibition if miRNA levels are low, as this promotes OPC
proliferation.
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studies.
The role of miRNAs in the generation of myelin was demon-
strated in a mouse model in which conditional ablation of the en-
zyme Dicer in the oligodendrocyte lineage cells resulted in a
fundamental disturbance of myelination [53–55]. Particularly
two miRNAs, miR-219 and miR-338, are involved in myelination,
as could be demonstrated in these studies. It was shown that the
generation of miRNAs was not necessary for the generation of oli-
godendrocyte precursors. Only the post mitotic stadium of oligo
dendrocyte lineage cells is signiﬁcantly affected. Absence of miR-
NAs resulted in blocked myelination, although a great number of
oligodendrocyte precursors expressing platelet-derived growth
factor receptors (PDGFrs) were observed [53,55]. A recently sug-
gested model describes these miRNAs as ‘‘brakes’’ that defer the
proliferation of oligodendrocyte lineage cells, thereby triggering
myelination [56] and Fig. 1. Expression of Dicer is consistently
increased during oligodendrocyte differentiation [57]. Demyelina-
tion, oxidative damage, lipid accumulation, inﬂammation, astrocy-
tosis microgliosis, and ultimately neuronal degeneration and
axonal damage were observed due to the lack of miR-219 and its
target ELOVL7 (elongation of very long chain fatty acids protein
7) in a mouse model with a deletion of Dicer in mature oligoden-
drocytes [54].
Interestingly, having an impaired ability to differentiate over
time, oligodendrocyte lineage cells are present in demyelinating
multiple sclerosis lesions [58,59]. Remarkably, miR-219 and miR-
338 are signiﬁcantly heavily downregulated in chronic inactive
demyelinated MS lesions [20].
The functional importance of high levels of miR-219 and miR-
338 in oligodendrocyte lineage cells has been demonstrated. More
studies are needed to show the functional importance of low levels
of miR-219 and miR-338 and others in demyelinated multiple scle-
rosis lesions.
4. MiRNAs modulating the innate immune response
In the development and course of MS, many different compo-
nents of the innate and adoptive immune system play fundamental
roles (for review, see [60]).
Some miRNAs which appeared to be regulated in MS lesions or
MS patient blood were recently described as having regulatory
functions in the immune system [14] or in other autoimmune dis-
orders [61]. In rheumatoid arthritis (RA), miR-155 and miR-146a
were upregulated in synovial tissue [62] in comparison to controls.
Both of them were also upregulated in active MS lesions [20].
MiRNAs have the potential to regulate TLR signaling [63]. In an
early study, miRNA proﬁles of the human monocyte cell line
THP1 were determined after treatment with the Toll-like receptor
4 (TLR4) ligand, lipopolysaccharide (LPS) [64], which revealed a
strong upregulation of miR-146, miR-155 and miR-132. MiR-146a
was upregulated after treatment withmany different inﬂammatory
stimuli, such as other TLR ligands and cytokines like IL1b, whereby
its induction is obviously NF-jB dependent. Notably, astrocytes ex-
press several TLRs [65] and their miRNA levels change strongly after
many different inﬂammatory stimuli [20]. MiR-146a was remark-
ably inducible in vitro, especially after stimulation with IL1b [20].
TRAF-6 and IRAK-1, two key TLR4 signaling proteins were
shown to be mRNA targets of the miR-146a [64] and Fig. 2. It
was recently reported that miR-146a functions as a negative
regulator of IL8 and RANTES production, whereas negative regula-
tion of TRAF-6 and IRAK-1 was not seen [66]. It seems likely that
miR-146a represents a negative regulator of TLR signaling [64].
In murine bone marrow-derived macrophages, miR-155 was
upregulated in response to the TLR3 ligand poly-inositolcytidine(poly(I:C)) and interferon beta [67]. The group identiﬁed upregula-
tion of miR-155 as dependent on the MAP kinase JNK [67]. The
induction of this miRNA was also reported from other groups
[68–70]. In the lung, diverse miRNAs, including miR-214, miR-21
miR-223 and miR-142-3p, are upregulated after a short time peri-
od of only one to three hours after treatment with LPS [71]. These
miRNAs were also found to be upregulated in active MS lesions in
comparison to controls [20]. Involvement of TLR signaling and its
effect on miRNA levels was investigated in another study in which
infection of cholangiocytes with cryptosporidium parvum or treat-
ment with LPS led to downregulation of the miR-let 7i. This miRNA
appeared to be regulated in two independent miRNA MS proﬁling
studies [29,30]. It was shown to be downregulated in whole blood
samples from MS patients [29] and upregulated in CD4+CD25high
bona ﬁde Treg cells from MS patients versus healthy donors [30].
A predicted target of this miRNA is TLR4 itself, and overexpression
of miR-let 7i accompanied by reciprocal expression of this TLR4 has
been previously observed [72].
5. MiRNAs modulating the adaptive immune response
Early studies connecting miRNAs to T cell function showed
abnormalities in Dicer-deﬁcient T cells. Dicer knockout resulted
in a deviant helper T cell differentiation and cytokine production.
CD8+ T cell differentiation was defective in the absence of Dicer,
and a low number of CD4+ T cells was produced which were lim-
ited in their proliferation after stimulation and which had an in-
creased apoptosis rate [73,74].
MiRNA proﬁling of CD4+ CD25+ Treg cells revealed an upregula-
tion of distinct miRNAs, such as miR-21, miR-146a, miR-223, miR-
214, miR-125a and miR-155, in comparison to naive T cells [75].
Other miRNAs, such as miR-150 and miR-142-5p, were downregu-
lated in Treg cells [75]. Expression of most of these miRNAs could
be induced by overexpression of the Treg-speciﬁc transcription
factor FoxP3. This miRNA proﬁle appeared to be similar to the pro-
ﬁle of activated CD4+ T helper cells [75].
Treg cells are thought to play an eminent role in the pathogen-
esis of MS, which could be demonstrated in MS patients as well as
Fig. 2. miR-146a modulates TLR signaling: In addition to other miRNAs, miR-146a
is potentially involved in the modulation of TLR signaling. Two important molecules
of TLR4 signaling, TRAF-6 and IRAK-1, are targets of this miRNA. The overexpression
of miR-146a caused by the upregulation of TLR-induced genes might thus inﬂuence
the signaling in a reciprocal way.
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miR-21, miR-146a, miR-223, miR-215 and miR-155 were all upreg-
ulated in active MS lesions [20]. A direct connection between this
striking similarity of miRNA proﬁles of CD4+ CD25+ Treg cells and
active MS lesions remains to be proven.
One recent study focused on alterations of miRNAs in CD4+
CD25+ Treg cells in MS patient blood versus controls [30]. In this
study, 23 humanmiRNAs were identiﬁed as being differentially ex-
pressed between CD4+CD25high bona ﬁde Treg cells from MS pa-
tients vs. healthy donors. Some members of the miR-106b-25
cluster were found to be downregulated in MS patients when com-
pared to healthy donors in CD4+CD25high CD127dim/- Treg cells. The
group focused on miR-106b and miR-25 from this cluster, which
were previously shown to modulate the TGF-beta signaling path-
way through their action on CDKN1A/p21 and BCL2L11/Bim [77].
TGF-beta is involved in Treg cell differentiation and maturation
[78–81]. Therefore, the deregulation of this miRNA cluster may al-
ter Treg cell activity in the course of MS by altering TGF-beta bio-
logical functions. Some of the miRNAs which were described by De
Santis and colleagues were also previously found in other studies
describing altered miRNA expression in MS (see Table 1).
Autoreactive T cells against myelin proteins occur in all healthy
individuals [46,47].
Do altered miRNAs in these cells provide one missing link dis-
criminating aggressive versus non-aggressive T cells in MS patients
versus healthy subjects?
Some miRNAs regulated in MS have been described as having
an inﬂuence on T cell pathogenicity. MiR-155 was shown to have
an impact on Th-17 development [48], as did miR-326 [31]. Both
of them are highly upregulated in the brain of MS patients [20].
Aspects of the impact of miRNAs involved in the pathophysiol-
ogy of MS on the proliferation, activation and differentiation of
CD4+ T cells are depicted in Fig. 3.
In the following, a selection of miRNAs prominently involved in
the regulation of immune cells or brain resident cells, which were
found to be regulated in studies with MS patient blood or MS brain
lesions, will be discussed in detail.
5.1. MiR-155
MiR-155 was among the most upregulated miRNAs in active MS
lesions compared to control brain specimens [20]. In this study its
level is more than 10-fold higher in MS lesion tissue than in respec-
tive control tissue.MiR-155 is a miRNA with many different functions in the im-
mune system. MiR-155-deﬁcient mice display considerable im-
mune defects. Notably, the B cell response and the Th2 helper T
cell response are affected [68,69]. MiR-155 is important for pro-
duction of antigen-speciﬁc IgGs [68,69,82]. Apart from this, miR-
155 expression is dramatically increased in CD4+ T cells upon their
activation, suggesting a functional importance for this miRNA in
activated T cells [83]. Many targets of miR-155 with potential
immunological relevance have been identiﬁed by expression pro-
ﬁling. Transcription factors such as c-Maf, cytokines and signal
proteins are targets of miR-155 (for review see [84]). C-Maf func-
tions as a promoter of Th2 cell development [68], while SOCS1, an-
other target of miR-155, is repressed by miR-155 in both
FoxP3+CD4+ Treg cells and FoxP3- CD4+ T cells, and impacts Treg
cell ﬁtness [85]. A complex picture of how miR-155 affects T cell
developmental pathways is imminent and it appears to involve
many targets and pathways. This may also be true for miR-155’s
positive role in Th17 cell development [48].
Interestingly, depletion of miR-155 leads to a reduction of tu-
mor necrosis factor alpha (TNFa) mRNA, suggesting a positive reg-
ulation of TNFa production by miR-155 [69]. Consistently,
upregulation of miR-155 provoked by exposure to LPS also en-
hances TNFa production [70].
In active lesions in the brain of MS patients, macrophages and
activated microglia are the predominant cell types. MiR-155 plays
an important role in macrophage response to inﬂammatory stimuli
[67]. This is partially achieved by targeting SMAD2 and thereby
inﬂuencing the TGF-beta signaling [86]. It was recently shown that
this miRNA has a direct effect on the regulation of macrophage
phenotype by targeting IL13Ra1 [87]. Expression of miR-155 is
upregulated by inﬂammatory cytokines such as TNFa or IL-1 in
astrocytes [20]. Along with other miRNAs, miR-155 targets the sur-
face protein CD47 [20], which is downregulated in chronic active
[88] and active [20] MS lesions. CD47 inhibits the phagocytic activ-
ity of macrophages [89–91] and cytokine production of dendritic
cells via signal regulatory protein-a [92]. Owing to its inhibitory ef-
fect on macrophages, CD47 has been regarded as a ‘don’t eat me
signal’ and as a ‘marker of self’ [90,91]. By having an inﬂuence on
the expression of CD47, miR-155 might have a direct effect on
the activity of macrophages in active MS lesions [20].
The importance of CD47 as a marker of self is also supported by
the observation that interspecies incompatibilities of CD47 con-
tribute to the rejection of xenogeneic grafts by macrophages [93].
In line with this, miR-155 overexpression was observed to be
upregulated in acute rejection reactions of renal allografts com-
pared to normal renal allografts [94].
One of the properties of miR-155 is the promotion of T cell-
dependent tissue inﬂammation. Mice with a deﬁciency of this miR-
NA are resistant to the development of active EAE, a model system
for multiple sclerosis [48].
MiR-155 and its star-form partner miR-155⁄ were induced at
different time points during stimulation of Toll-like receptor 7
(TLR7) in plasmacytoid dendritic cells (PDCs), and it was demon-
strated that they regulate the interferon production in PDCs [95].
In doing so, miR-155⁄ augmented interferon-a/b expression by
suppressing IRAKM, whereas miR-155 inhibited their expression
by targeting TAB2.
Due to its various functions in the immune system, it is likely
that miR-155 also has different functions in MS pathology. This
might be true also for other miRNAs regulated in the blood or brain
tissue of MS patients.
5.2. MiR-326
MiR-326 might also be critically involved in the pathogenesis of
MS. It is one of the most upregulated miRNAs in MS lesions and it
Fig. 3. miRNAs in the differentiation and function of CD4+ T cells: Diverse miRNAs have been described in modulating the proliferation and activation of naïve CD4+ T cells.
The miR-17-92 cluster is one important example for this modulation. In a mouse model, the miR-17-92 cluster contributes to the development of autoimmunity and induces
a lymphoproliferative disease [50]. In this model, the number of mature CD4+ T cells was markedly increased and they had a highly activated proﬁle. MiRNAs were also
described in the differentiation of naïve CD4+ T cells. MiR-155 promotes the differentiation of inﬂammatory T cells, including the T helper 17 (Th17) cell and Th1 cell subsets.
The transcription factor C-Maf is targeted and downregulated by miR-155. By the lack of this transcription factor, which has an important role in the development of Th2 cells,
the differentiation is shifted towards the Th1 phenotype. By targeting Ets-1, a known negative regulator of Th-17 differentiation, miR-326 is able to promote Th-17
differentiation. MiR-106b and miR-25 were shown to regulate the TGF-beta signaling pathway by targeting CDKN1A/p21 and BCL2L11/Bim [49]. Treg cell differentiation and
maturation is modulated by TGF-beta [78–81].
A. Junker / FEBS Letters 585 (2011) 3738–3746 3743was found to be upregulated during relapses in the blood of MS pa-
tients [31]. In an animal model, inhibition of miR-326 was shown
to reduce EAE symptoms by preventing Th17 cell differentiation
through a T cell-intrinsic mechanism [31]. It was shown that
miR-326 targets Ets-1, a known negative regulator of Th-17 cells.
MiR-326 promoted the generation of Th-17 cells both in vivo in
mice and in vitro [31].
5.3. MiR-223
Another example of a miRNA which could be involved in the
pathogenesis of MS is miR-223. Originally, it was described in
the regulation of granulopoesis. Mice with a deﬁciency of miR-
223 have an increased number of granulocyte precursors which
are hypermature and particularly sensitive to activating stimuli
[96]. Hence it could be shown that miR-223 was an important neg-
ative regulator of granulopoesis by targeting the transcription fac-
tor Mef-2c. Another study indicates that miR-223 is critical in
macrophage differentiation [97]. By targeting transcripts of the ki-
nase IKKa, miR-223 together with miR-15a and miR-16 modulate
the NF-jB pathway. Thus a downregulation of these miRNAs might
prevent macrophage hyperactivation. MiR-223 also occurs in CD4+
CD25+ Treg cells, where it appeared upregulated in comparison to
naive T cells [75].
Up to now, three studies showed an upregulation of this miRNA
in the context of MS (see Table 1). It was found upregulated in the
blood of MS patients compared to healthy controls [32], as well as
in CD4+CD25high bona ﬁde Treg cells from MS patients [30] versus
comparable cells from healthy donors, and also in active MS lesions
in the brain compared to normal brain specimens [20].
5.4. MiR-142-3p
MiR-142 is located on chromosome 17 at a site which is associ-
ated with a translocation in B cell lymphoma [98,99]. This miRNA
is among the most highly expressed miRNAs in many hematopoi-
etic lineages, T cells and B cells as well as in stem cells, and its
expression also depends on the activation state of the cell type
[100,101].
A low level of intracellular cAMP is needed for the activation of
conventional CD4+ T cells, whereas naturally occurring Treg cellscontain high levels of cAMP and exert their suppressor function
by transferring cAMP into conventional T cells through gap junc-
tions [102]. MiR-142-3p also has the potential to target AC9 mRNA
in T cells, which restricts cAMP production [103]. This effect might
not be restricted to T cells but may also play a role in other cell
types.
5.5. MiR-148a
So far, two studies have demonstrated the connection between
miR-148a and MS. This miRNA was upregulated in the brain in
inactive MS lesions versus controls [20] and in CD4+CD25high bona
ﬁde Treg cells from MS patients versus controls [30].
Recently, interesting functions of miR-148a in the immune sys-
tem were observed. MiR-148a could inhibit LPS-induced upregula-
tion of MHC II expression on DCs [104]. Moreover it was able to
inhibit DC production of cytokines, especially including IL-12 after
various stimuli [104]. It seems that miR-148a acts as a negative
regulator for the innate response and APC function of DCs.
Another study provided evidence that dysregulation of miR-
148a is involved in SLE, which inhibits DNA methyltransferase 1
(DNMT1) expression and promotes DNA hypomethylation in lupus
CD4+ T cells [105]. This in turn leads to the overexpression of auto-
immune-associated methylation-sensitive genes, such as CD70 and
LFA-1, via promoter demethylation.
Adoptive transfer of T cells made autoreactive by treatment
with DNA methylation inhibitors or by transfection with LFA-1 is
sufﬁcient to cause a lupus-like disease in mice [106,107].
5.6. MiR-126
Another miRNA, miR-126, which is dysregulated in the blood
[29,33] and inactive brain lesions of MS patients [20], was also re-
ported to target DNMT1, thus regulating the activity of CD4+ T cells
in SLE [108]. In other studies it was shown that miR-126 [109,110]
and its host transcript Egﬂ7 [111] are expressed in endothelial
cells.
In vivo application of a complementary sequence to miR-126, a
so-called antagomiR, showed a markedly reduced angiogenic re-
sponse in an experimental ischemia mouse model in which ische-
mia was induced in the hind limb by ligation of an artery [112]. It
3744 A. Junker / FEBS Letters 585 (2011) 3738–3746was suggested that miR-126 increases the sensitivity of activated
endothelial cells to VEGF or other growth factors by directly
repressing negative regulators of the VEGF pathway, including
the Sprouty-related protein, SPRED1, and phosphoinositol-3 kinase
regulatory subunit 2 (PIK3R2) [113].
5.7. MiR-497
What the function miR-497 is in autoimmune disease has yet to
be investigated. It was upregulated in CD4+ T cells and B cells, but
downregulated in CD8+ T cells in MS patients compared with the
expression in control subjects [33]. Apart from this, it was upregu-
lated in inactive MS brain lesions versus controls. Recently it was
suggested that miR-497 promotes ischemic neuronal death by neg-
atively regulating the antiapoptotic proteins bcl-2 and bcl-w [114].
Because of the regulation of this antiapoptotic pathway, miR-497
may contribute to the pathogenesis of ischemic brain injury in
stroke [114]. Future studies will have to clarify whether this also
plays a role in degenerative processes of the MS brain.
5.8. MiR-34a
Two different studies showed a regulation of miR-34a in MS.
MiR-34a was upregulated in active MS lesions and downregulated
in CD4+ T cells in blood samples from MS patients versus controls.
Only recently, miR-34a together with other related miRNAs
(miR-34b and miR-34c) were identiﬁed as transcriptional targets
of p53. Furthermore, He and colleagues demonstrated that they
were able to target mRNA transcripts, which are important in cell
cycle progression and cell survival [115]. They showed that miR-34
family miRNAs mediate growth arrest in a variety of cell types.
Interestingly, a speciﬁc role for miR-34a during neuronal differen-
tiation has been uncovered lately. Upregulation of miR-34a during
mouse neuronal stem cell differentiation was found and this ap-
peared in parallel to the development of postmitotic neurons
[116]. Some potential miR-34a target transcripts might be involved
in the transition towards postmitotic neurons. Previously it was
shown that miR-34a targets silent information regulator 1 (SIRT1)
[117]. MiR-34 inhibition of SIRT1 leads to an increase in acetylated
p53 and expression of p21 and PUMA, which are transcriptional
targets of p53 [117]. As miR-34a itself is a transcriptional target
of p53 this interaction suggests a positive feedback loop between
p53 and miR-34a [117].6. Concluding remarks and future perspectives
Although the examinations of blood and tissue from patients
are always only snapshots of miRNA expression, and the behavior
of miRNAs during a certain process in MS is difﬁcult to determine,
there are until now several overlaps between the expression pro-
ﬁles of miRNA in MS in the published studies (for summary see Ta-
ble 1).
The key question as to whether it will be possible to deﬁne dif-
ferent disease entities of MS with speciﬁc miRNA proﬁles remains
open up to now. There is a good chance that future miRNA proﬁling
studies will provide an answer to this question.
Whether those miRNAs described in the recent MS proﬁling
studies might serve as valuable diagnostic markers for a speciﬁc
state of the disease will be evaluated in future studies. Moreover,
their value as therapeutic markers for the selection of individual
therapies or as proof of the therapeutic effects of particular drugs
still needs to be determined.
Many of the miRNAs regulated in the blood or CNS lesions of MS
patients have been identiﬁed as key regulators of immune cell
development and function, as well as master gene regulators ofphysiological and pathological processes of other brain-resident
cells, such as oligodendrocytes or astrocytes. The second key ques-
tion - as-yet unanswered - is whether altered miRNAs in the im-
mune cells provide a missing link towards discriminating
aggressive versus non-aggressive cell subsets in MS patients versus
healthy subjects.
The observation that a single miRNA can have several effects on
different cellular lineages indicates that functional miRNA targets
may vary in individual cell types and their diverse activation and
differentiation stages. Thus one miRNA might have many roles,
starting from guidance of cell development to the activation and
modulation of immune cells.
One major goal in the next few years will be to understand the
pathophysiology of the human disease MS and to ﬁnd appropriate
pharmaceuticals to combat the disease. A better understanding of
MiRNAs is essential for both of these efforts.
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